Abbott accelerates PFA market competition in Europe with early Volt approval
The highly competitive pulsed field ablation (PFA) market is welcoming a new entrant after Abbott secured CE marking for its…
Cardiovascular
-
-
Abbott eyes intravascular lithotripsy market with clinical trial approval
The US Food and Drug Administration (FDA) has granted Abbott an investigational device exemption to evaluate the company’s coronary intravascular…
-
Cardiac Dimensions snags $53m for mitral valve device
Cardiac Dimensions has secured $53m in a Series E funding round to support its ongoing pivotal trial assessing the company’s…
-
UVA School of Medicine creates tool to predict drug impact on biological process
School of Medicine scientists at the University of Virginia (UVA), US have developed an AI tool, LogiRx, designed to expedite…
-
AngioInsight to assess AI-powered platform for cardiovascular diagnosis
US-based AngioInsight is set to launch its pivotal SMARTFLOW clinical study to assess its AI-powered, software-only AngioAI+ platform’s diagnostic accuracy…
-
Laplace raises funding to complete study of tricuspid valve technology
US medical device company Laplace Interventional has completed a Series C financing round to support the completion of an early…
-
FDA approves early feasibility study of Valcare’s transcatheter device
The US Food and Drug Administration (FDA) has granted approval for Valcare Medical’s investigational device exemption application, allowing it to…
-
Medtronic announces two-year trial outcomes of Evolut TAVR
Medtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial’s two-year outcomes of the Evolut transfemoral transcatheter aortic valve replacement (TAVR)…
-
Capstan Medical’s robotic platform used for first mitral valve replacements
Capstan Medical’s robot platform has been used for the first in-human robotic assisted transcatheter mitral valve replacement procedures, confirming the…
-
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin
Cadrenal Therapeutics has entered a partnership with Abbott for the tecarfarin anticoagulation and haemocompatibility with left ventricular assist devices (TECH-LVAD) trial.…
